Healthcare Insights
Most common antidepressants
Antidepressants are widely prescribed in the U.S., where, according to the National Institute of Mental Health, nearly 21 million adults are affected by one or more major depressive disorders.
For biopharmaceutical companies, behavioral health organizations, and other businesses looking to enter or compete effectively in this space, understanding the latest trends impacting the antidepressant market can be invaluable to your growth strategy.
Using data from the Atlas All-Payor Claims Dataset, we’ve compiled a list of the most common antidepressants prescribed and dispensed to patients across the U.S. during 2023.
Rank | Drug name | % of total prescriptions | Explore dataset |
---|---|---|---|
1 | Sertraline Hydrochloride | 16.73% | Explore |
2 | Trazodone Hydrochloride | 15.41% | Explore |
3 | Fluoxetine | 12.64% | Explore |
4 | Duloxetine | 11.27% | Explore |
5 | Escitalopram | 10.89% | Explore |
6 | venlafaxine hydrochloride | 7.71% | Explore |
7 | Escitalopram Oxalate | 6.55% | Explore |
8 | Citalopram Hydrobromide | 4.39% | Explore |
9 | Paroxetine | 3.63% | Explore |
10 | Sertraline | 3.63% | Explore |
What are the most common antidepressant medications?
Ranking first on our antidepressants list is sertraline hydrochloride. This prescription medication, more commonly known by its brand name Zoloft, accounted for 16.73% of total antidepressants prescribed and dispensed in the U.S. in 2023. This drug is a selective serotonin reuptake inhibitor, which works by increasing the levels of serotonin in the brain to regulate mood.
In second place is trazodone hydrochloride with 15.41% of total prescriptions. Trazodone is classified as a serotonin antagonist and reuptake inhibitor (SARI), meaning it helps increase serotonin levels in the brain to improve mood while also promoting relaxation and sleep. In part because of this, trazodone is sometimes prescribed to treat insomnia due to its sedative effects.
Fluoxetine comes in third place. Commonly known by the brand name Prozac, this drug accounted for 12.64% of prescriptions and belongs to the selective serotonin reuptake inhibitor class. It’s widely used to treat several mental health conditions by increasing serotonin levels in the brain, and helping improve mood, sleep, and energy levels. It’s also used off-label for conditions like generalized anxiety disorder (GAD) and post-traumatic stress disorder (PTSD).
What are the different types of antidepressants?
Antidepressant medications can fall into a number of different categories based on how the drug affects the body’s chemistry. The main types of antidepressants include:
Selective serotonin reuptake inhibitors (SSRIs)
SSRIs generally have fewer side effects than other types of antidepressants, which contributes to the number of people who take SSRIs. The top two medications on the list above - sertraline and escitalopram – are examples of SSRI antidepressant medications.
Serotonin and norepinephrine reuptake inhibitors (SNRIs)
SNRIs work similarly to SSRIs but affect both serotonin and norepinephrine in the brain. The medication in sixth place on the list above, duloxetine, is an example of an SNRI medication.
Atypical antidepressants
Atypical antidepressants represent medications that work slightly differently than the other types of antidepressant medications. The drugs trazodone and bupropion on the list above are examples of atypical antidepressant medications.
Tricyclic antidepressants
Tricyclic antidepressants are some of the earliest types of antidepressant medications. They have some increased risks of side effects so they are less frequently prescribed today and are often reserved for patients with more treatment-resistant conditions.
Monoamine oxidase inhibitors (MAOIs)
MAOIs are the first type of antidepressant medications developed and have mostly been replaced with the more popular antidepressant medication types, such as SSRIs and SNRIs, due to their fewer side effects.
How trends in antidepressant prescription are changing healthcare
With the landscape of mental health care evolving, trends in antidepressant prescription point to several strategic opportunities for biopharma and behavioral health organizations looking to compete or bring new treatments into the market.
Below are a few of the emerging trends we’re watching:
Rising demand for nontraditional therapeutics
Interest in psychedelic-assisted therapy and NMDA receptor modulation (e.g., ketamine-based treatments) is increasing. Companies considering entry into these innovative areas may benefit from early R&D investment and strategic partnerships with mental health practitioners open to novel therapies. We touch upon the implications of psilocybin and other medications for treating major depressive disorders in our trends blog on the rise of non-opioid pain management.
Digital therapeutics are changing how mental health care is seen and treated
Digital therapeutics are evidence-based therapeutic interventions that are driven by software. They aim to prevent, treat, or manage medical diseases or disorders using mobile devices, sensors, apps, virtual reality, and other tools.
While the most common digital therapeutics are mobile health apps that help people exercise or eat healthier, there is an emerging subset of software designed specifically for patients with mental or behavioral health conditions.
The applications and potential benefits of these apps are among the most talked about in healthcare today. Digital therapeutics are helping overworked physicians focus on the patients most in need of care while still supporting less critical patients through remote education, monitoring, and improved care coordination. For biopharma and behavioral health organizations looking for a competitive edge, researching and investing in digital therapeutics may be the solution.
Mental healthcare is finding a new home in urgent care centers
The shift of mental health patients seeking care at urgent care centers (UCCs) reflects a broader transformation in healthcare delivery, driven by factors like limited mental health provider availability, lengthy wait times for psychiatric services, and growing demand for convenient, immediate access to care.
The demand for mental health treatment at UCCs is altering the typical prescribing landscape and presents a unique opportunity for biopharma companies.
One example is the kind of medications UCCs most commonly prescribe. These facilities tend to prescribe drugs that are easy to initiate and monitor, such as SSRIs, because some treatments have lower monitoring requirements and a favorable safety profile. Biopharma companies can adjust their product positioning to strategically highlight the efficacy and ease of use of their medications to more effectively sell to UCCs and increase market share.
Learn more
Healthcare Insights are developed with healthcare commercial intelligence from the Definitive Healthcare platform. Want even more insights? Start a free trial now and get access to the latest healthcare commercial intelligence on hospitals, physicians, and other healthcare providers.